Hokuriku Pharmaceutical: Notice on holding the 3rd Bondholders\' Meeting in 2023
Hokuriku Pharmaceutical: Notice on holding the second bondholders\' meeting in 2023
Hokuriku Pharmaceutical: 2021 Annual Dividend Implementation Notice
Hokuriku Pharmaceutical: Announcement on Hokuriku Convertible Bonds Resale Results
Hokuriku Pharmaceutical: Third indicative announcement on the resale of Hokuriku convertible bonds
Hokuriku Pharmaceutical: Second indicative announcement on the resale of Hokuriku convertible bonds
Hokuriku Pharmaceutical: First Prompt Announcement on Hokuriku Convertible Bonds Resale
Hokuriku Pharmaceutical: Announcement of Resolutions of the First Meeting of Bondholders in 2022
Hokuriku Pharmaceutical: Notice on holding the first meeting of Hokuriku debt holders in 2022
Hokuriku Pharmaceutical: Convertible Corporate Bond Interest Payment Notice
Hokuriku Pharmaceutical: Announcement on price adjustments for convertible corporate bonds to shares
Hokuriku Pharmaceutical: Announcement on the controlling shareholder's holdings of convertible corporate bonds
Hokuriku Pharmaceutical: Announcement on the Board's proposal to revise the convertible corporate bond conversion price downward
Hokuriku Pharmaceutical: Announcement on the issuance of convertible corporate bonds to unspecified targets
Hokuriku Pharmaceutical: A letter of sponsorship from CITIC Construction Investment Securities Co., Ltd. regarding the issuance of convertible corporate bonds to unspecified targets and listing on the GEM
Hokuriku Pharmaceutical: Prompt Announcement on Issuance of Convertible Corporate Bonds Prospectus to Unspecified Targets
Hokuriku Pharmaceutical: Online Roadshow Announcement on Issuance of Convertible Corporate Bonds to Unspecified Targets
Hokuriku Pharmaceutical: Credit Rating Report on GEM's Public Offering of Convertible Corporate Bonds
Hokuriku Pharmaceutical: Announcement on the application for issuing convertible corporate bonds to unspecified targets and obtaining registration approval from the China Securities Regulatory Commission
Hokuriku Pharmaceutical: 1. Replies from Hokuriku Pharmaceutical and CITIC Construction Investment to the implementation letter of the GEM Listing Committee's review
No Data
No Data